Chapter 38. Selected Management of Patients with Myelodysplastic Syndromes

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director3,4,
  2. Jeff Ginsberg MD, FRCPC Professor5,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor6,7,
  4. Ralph M. Meyer MD, FRCPC Director Professor8,9 and
  5. Richard Lottenberg MD, FACP Professor10
  1. John M. Storring MD1 and
  2. Karen W. L. Yee MD2

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch38

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Storring, J. M. and Yee, K. W. L. (2009) Selected Management of Patients with Myelodysplastic Syndromes, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch38

Editor Information

  1. 3

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 4

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 5

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 6

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 7

    McMaster University, Hamilton, Canada

  6. 8

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 9

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 10

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. 1

    McGill University Health Centre, Montreal, Quebec, Canada

  2. 2

    Department of Medical Oncology and Hematology, University Health Network—Princess Margaret Hospital, Toronto, Ontario, Canada

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • myelodysplastic syndromes (MDS);
  • role of lenalidomide in patients with previously untreated or treated MDS;
  • hypomethylating agents, azacitidine and decitabine in patients with MDS;
  • reasonable management approach using drug therapy for MDS;
  • azacitidine for treatment-related or de novo MDSFAB subtypes - refractory anemia (RA);
  • ringed sideroblasts (RARS);
  • chronic myelomonocytic leukemia (CMML) (Grade 1B)

Summary

This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature search and inclusion

  • What is the role of lenalidomide in patients with previously untreated or treated MDS?

  • What is the role of the hypomethylating agents, azacitidine and decitabine, in patients with MDS?

  • What constitutes a reasonable management approach to using drug therapy for patients with MDS?

  • References